Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized Alpharadin in symptomatic prostate cancer trial.

2.50
Hdl Handle:
http://hdl.handle.net/10541/620492
Title:
Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized Alpharadin in symptomatic prostate cancer trial.
Authors:
Parker, C; Coleman, R; Sartor, O; Vogelzang, N; Bottomley, D; Heinrich, D; Helle, S; O'Sullivan, J; Fosså, S; Chodacki, A; Wiechno, P; Logue, John P; Seke, M; Widmark, A; Johannessen, D; Hoskin, P; James, N; Solberg, A; Syndikus, I; Kliment, J; Wedel, S; Boehmer, S; Dall'Oglio, M; Franzén, L; Bruland, O; Petrenciuc, O; Staudacher, K; Li, R; Nilsson, S
Abstract:
In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-223 monitoring underlies a comprehensive safety and risk/benefit assessment.
Affiliation:
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK
Citation:
Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized Alpharadin in symptomatic prostate cancer trial. 2017 Eur Urol
Journal:
European Urology
Issue Date:
10-Jul-2017
URI:
http://hdl.handle.net/10541/620492
DOI:
10.1016/j.eururo.2017.06.021
PubMed ID:
28705540
Type:
Article
Language:
en
ISSN:
1873-7560
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorParker, Cen
dc.contributor.authorColeman, Ren
dc.contributor.authorSartor, Oen
dc.contributor.authorVogelzang, Nen
dc.contributor.authorBottomley, Den
dc.contributor.authorHeinrich, Den
dc.contributor.authorHelle, Sen
dc.contributor.authorO'Sullivan, Jen
dc.contributor.authorFosså, Sen
dc.contributor.authorChodacki, Aen
dc.contributor.authorWiechno, Pen
dc.contributor.authorLogue, John Pen
dc.contributor.authorSeke, Men
dc.contributor.authorWidmark, Aen
dc.contributor.authorJohannessen, Den
dc.contributor.authorHoskin, Pen
dc.contributor.authorJames, Nen
dc.contributor.authorSolberg, Aen
dc.contributor.authorSyndikus, Ien
dc.contributor.authorKliment, Jen
dc.contributor.authorWedel, Sen
dc.contributor.authorBoehmer, Sen
dc.contributor.authorDall'Oglio, Men
dc.contributor.authorFranzén, Len
dc.contributor.authorBruland, Oen
dc.contributor.authorPetrenciuc, Oen
dc.contributor.authorStaudacher, Ken
dc.contributor.authorLi, Ren
dc.contributor.authorNilsson, Sen
dc.date.accessioned2017-08-08T13:45:39Z-
dc.date.available2017-08-08T13:45:39Z-
dc.date.issued2017-07-10-
dc.identifier.citationThree-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized Alpharadin in symptomatic prostate cancer trial. 2017 Eur Urolen
dc.identifier.issn1873-7560-
dc.identifier.pmid28705540-
dc.identifier.doi10.1016/j.eururo.2017.06.021-
dc.identifier.urihttp://hdl.handle.net/10541/620492-
dc.description.abstractIn Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-223 monitoring underlies a comprehensive safety and risk/benefit assessment.en
dc.language.isoenen
dc.rightsArchived with thanks to European urologyen
dc.titleThree-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized Alpharadin in symptomatic prostate cancer trial.en
dc.typeArticleen
dc.contributor.departmentThe Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UKen
dc.identifier.journalEuropean Urologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.